Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.
The device maker designed the lead to have the safety benefits of small-diameter devices without sacrificing durability.
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) ...
Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates Medtronic is the first and only ...
Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny ...
The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate ...
Labeling for a Medtronic pacing lead, already indicated for stimulation of the His bundle, has been expanded to include the left bundle branch (LBB), the company announced today. The US Food and Drug ...
Medtronic has secured a new approval from the FDA that expands the flexibility of its pacemaker hardware, allowing it to tap into the heart’s natural electrical signals. Known as conduction system ...
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: ...